Oct 01, 2021 · Thrombocytosis, unspecified 2016 2017 2018 2019 2020 2021 2022 Billable/Specific Code D75.839 is a billable/specific ICD-10-CM code that can be used to indicate a diagnosis for reimbursement purposes. The 2022 edition of ICD-10-CM D75.839 became effective on October 1, 2021.
Oct 01, 2021 · The 2022 edition of ICD-10-CM D75.83 became effective on October 1, 2021. This is the American ICD-10-CM version of D75.83 - other international versions of ICD-10 D75.83 may differ. Type 2 Excludes essential thrombocythemia ( D47.3) The following code (s) above D75.83 contain annotation back-references that may be applicable to D75.83 : D50-D89
Oct 01, 2021 · Essential (hemorrhagic) thrombocythemia 2016 2017 2018 2019 2020 2021 2022 Billable/Specific Code D47.3 is a billable/specific ICD-10-CM code that can be used to indicate a diagnosis for reimbursement purposes. The 2022 edition of ICD-10-CM D47.3 became effective on October 1, 2021.
Search Results. 415 results found. Showing 1-25: ICD-10-CM Diagnosis Code D47.3 [convert to ICD-9-CM] Essential (hemorrhagic) thrombocythemia. Essential thrombocythemia; Thrombocytosis; Thrombocytosis (high blood platelets); reactive thrombocytosis (D75.838); secondary thrombocytosis (D75.838); thrombocythemia NOS (D75.839); thrombocytosis NOS …
A type 2 excludes note represents "not included here". A type 2 excludes note indicates that the condition excluded is not part of the condition it is excluded from but a patient may have both conditions at the same time. When a type 2 excludes note appears under a code it is acceptable to use both the code ( D75.83) and the excluded code together.
D50-D89 Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism
D75.83 should not be used for reimbursement purposes as there are multiple codes below it that contain a greater level of detail.
A primary malignant neoplasm that overlaps two or more contiguous (next to each other) sites should be classified to the subcategory/code .8 ('overlapping lesion'), unless the combination is specifically indexed elsewhere.
The 2021 edition of ICD-10-CM D47.3 became effective on October 1, 2020.
Billable codes are sufficient justification for admission to an acute care hospital when used a principal diagnosis.
Thrombocytosis (or thrombocythemia) is the presence of high platelet counts in the blood, and can be either primary (also termed essential and caused by a myeloproliferative disease) or reactive (also termed secondary). Although often symptomless (particularly when it is a secondary reaction), it can predispose to thrombosis in some patients.
D75.83 is a non-specific and non-billable diagnosis code code , consider using a code with a higher level of specificity for a diagnosis of thrombocytosis. The code is not specific and is NOT valid for the year 2022 for the submission of HIPAA-covered transactions. Category or Header define the heading of a category of codes that may be further subdivided by the use of 4th, 5th, 6th or 7th characters.
A type 2 excludes note represents "Not included here". An excludes2 note indicates that the condition excluded is not part of the condition represented by the code, but a patient may have both conditions at the same time. When an Excludes2 note appears under a code, it is acceptable to use both the code and the excluded code together, when appropriate.
D75.83 is new to ICD-10 code set for the FY 2022, effective October 1, 2021. The National Center for Health Statistics (NCHS) has published an update to the ICD-10-CM diagnosis codes which became effective October 1, 2021. This is a new and revised code for the FY 2022 (October 1, 2021 - September 30, 2022).